Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enasidenib - Servier

Drug Profile

Enasidenib - Servier

Alternative Names: AG 221 mesylate; AG-221; AGI 12910 mesylate; AGI-12910; CC-90007; IDHIFA

Latest Information Update: 22 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agios Pharmaceuticals
  • Developer Agios Pharmaceuticals; Celgene Corporation; HOVON Foundation; Massachusetts General Hospital; University Health Network
  • Class Amines; Antineoplastics; Fluorinated hydrocarbons; Propanols; Pyridines; Small molecules; Triazines
  • Mechanism of Action Isocitrate dehydrogenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia
  • Phase III Myelodysplastic syndromes
  • Phase II Myelofibrosis; Myeloproliferative disorders
  • Phase I/II Solid tumours
  • No development reported Chronic myelomonocytic leukaemia

Most Recent Events

  • 22 Feb 2024 Celgene completes a phase I/II trial in Myelodysplastic syndromes in France and USA (PO) (NCT01915498)
  • 22 Dec 2023 Celgene completes a phase II trial in Acute myeloid leukaemia (Second-line therapy or greater) in Australia and South Korea (NCT03720366)
  • 09 Dec 2023 Final efficacy and adverse events data from the phase Ib/II ENAVEN-AML trial in Acute myeloid leukaemia and Myelodysplastic syndromes presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top